Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), received a high-level delegation from the global leadership of Takeda, headed by Dr. Khaled Sari, General Manager of the company, to discuss ways to strengthen joint cooperation and develop partnership areas between the two sides.
The meeting included discussions on mechanisms to support existing partnership projects between the Egyptian Drug Authority and Takeda. It also reviewed future cooperation opportunities in line with the Egyptian state's vision to support the health sector and develop the national pharmaceutical system.
Furthermore, the meeting featured a review of several initiatives and policies aimed at enhancing the availability of medicines for Egyptian patients. It also addressed joint mechanisms to facilitate access to innovative treatments, particularly in several priority therapeutic areas.
During the meeting, company representatives presented the latest updates on Takeda's activities in the field of clinical trials and scientific research within the Egyptian market. They emphasized the importance of continued coordination and cooperation with the Egyptian Drug Authority to enhance research activities and support the scientific research system in Egypt.
The company delegation was also briefed on the Authority’s vision and future directions regarding intellectual property rights for pharmaceutical products. This contributes to creating an attractive investment environment that complies with international standards and supports efforts to develop the pharmaceutical sector in Egypt.
Dr. Ali El-Ghamrawy stressed that the Authority places great importance on supporting research activities and enhancing the clinical trials system in Egypt. He noted that this contributes to establishing Egypt’s position as a regional hub for pharmaceutical research and development. He also pointed out the Authority's keenness to strengthen cooperation with leading international companies to exchange expertise and support pharmaceutical innovation, which reflects positively on the health of Egyptian patients.

For their part, the Takeda delegation expressed their appreciation for the fruitful cooperation with the Egyptian Drug Authority. They praised the role played by the Authority in supporting and developing the pharmaceutical system and enhancing the scientific research environment in Egypt. They confirmed the company's keenness to continue strengthening its activities within the Egyptian market and expanding in the fields of research, development, and clinical trials to support pharmaceutical innovation and provide the latest treatments to patients.
This comes within the framework of the Egyptian Drug Authority’s keenness to enhance communication with major international companies operating in the pharmaceutical industry and to support strategic partnerships that contribute to developing the pharmaceutical industry and achieving sustainable development in the health sector.